1. Volume 2, Issue 10, Pages 1494-1499 (October 2015)
Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster 
Alies van Lier, Anna Lugnér, Wim Opstelten, Petra Jochemsen, Jacco Wallinga, François Schellevis, Elisabeth Sanders, Hester de Melker, Michiel van Boven 
EBioMedicine 
Volume 2, Issue 10, Pages (October 2015)
DOI: /j.ebiom
Copyright © Terms and Conditions

2. Fig. 1
VZV seroprevalence in 2006–2007 (blue dots) and herpes zoster incidence in the period 2002–2011 (orange dots) in the Netherlands.
The sizes of the dots reflect sample sizes. Total numbers of sera and herpes zoster cases are 6251 and 7026, respectively. Thin grey lines indicate fits of transmission models with and without immune boosting. See the Supplement for details.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © Terms and Conditions

3. Fig. 2
Impact of varicella vaccination by birth cohort on the occurrence of varicella and herpes zoster.
The vaccination programme started in See Table 1 for an overview of scenarios.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © Terms and Conditions

4. Fig. 3
Impact of varicella vaccination over time on the occurrence of varicella and herpes zoster.
The vaccination programme started in See Table 1 for an overview of scenarios.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © Terms and Conditions

5. Fig. 4
Stylised overview of the cost-effectiveness of high-coverage (95%) varicella vaccination programme over time. Incremental cost-effectiveness ratio (ICER) threshold is set at €20,000 per QALY. This figure is based on data contained in Figures S10–S11. See the Supplement for details and sensitivity analyses.
EBioMedicine 2015 2, DOI: ( /j.ebiom )
Copyright © Terms and Conditions

6. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

7. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

8. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

9. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

10. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

11. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

12. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

13. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

14. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

15. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

16. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

17. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

18. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

19. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

20. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

21. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions

22. EBioMedicine 2015 2, 1494-1499DOI: (10.1016/j.ebiom.2015.08.017)
Copyright © Terms and Conditions